Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network

Antiviral Therapy

Volumn 12, Issue 8, 2007, Pages 1305-1310

  Chaix, Marie Laure ^a   Desquilbet, Loic ^b,c,d   Descamps, Diane ^e   Costagliola, Dominique ^b,g   Deveau, Christiane ^b,c,d   Galimand, Julie ^a   Goujard, Cécile ^f   Signori Schmuck, Anne ^h   Schneider, Veronique ⁱ   Tamalet, Catherine ^j   Pellegrin, Isabelle ^k   Wirden, Marc ^l   Masquelier, Bernard ^k   Brun Vezinet, Francoise ^e   Rouzioux, Christine ^a   Meyer, Laurence ^b,c,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d BICÊTRE HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

^f Service de Medecine Interne   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL TENON   (France)

^j TIMONE HOSPITAL   (France)

^k HÔPITAL PELLEGRIN   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FRANCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 38049013279     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
2. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-2292.
3. Pillay D, Cane PA, Shirley J, Porter K. Detection of drug resistance associated mutations in HIV primary infection within the UK. AIDS 2000; 14:906-908.
4. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282:1135-1141.
5. Brenner B, Wainberg MA, Salomon H, et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents 2000; 16:429-434.
6. Jayaraman GC, Archibald CP, Kim J, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006; 42:86-90.
7. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14:F17-23.
8. Fox J, Hill S, Kaye S, et al. Prevalence of primary genotypic resistance in a UK centre: Comparison of primary HIV-1 and newly diagnosed treatment-naive individuals. AIDS 2007; 21:237-239.
9. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
10. Harzic M, Pellegrin I, Deveau C, et al. Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. AIDS 2002; 16:793-796.
11. Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17:2635-2643.
12. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38:545-552.
13. Chan KC, Galli RA, Montaner JS, Harrigan PR. Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 2003; 17:1256-1258.
14. Brenner B, Routy JP, Quan Y, et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18:1653-1660.
15. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primarv infection. J Virol 2002; 76:1753-1761.
16. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683-1689.
17. Ghosn J, Pellegrin I, Goujard C, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20:159-170.
18. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37:1570-1573.
19. Bhaskaran K, Pillay D, Walker AS, et al. Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS 2004; 18:1471-1473.
20. Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365:1031-1038.
21. Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primarv HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42:709-715.
22. Desquilbet L, Deveau C, Goujard C, Hubert JB, Derouineau J, Meyer L. Increase in at-risk sexual behaviour among HIV-1-infected patients followed in the French PRIMO cohort. AIDS 2002; 16:2329-2333.
23. Schiffer V, Deveau C, Meyer L, et al. Recent changes in the management of primarv HIV-1 infection: results from the French PRIMO cohort. HIV Med 2004; 5:326-333.
24. Flandre P, Durier C, Descamps D, Launay O, Joly V. On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases. J Acquir Immune Defic Syndr 2002; 30:59-64.
25. Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: Statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retroviral 1999; 20:220-227.
26. Flandre P, Alcais A, Descamps D, Morand-Joubert L, Joly V. Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data. J Acquir Immune Defic Syndr 2004; 35:286-292.
27. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
28. Tamalet C, Pasquier C, Yahi N, et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primarv HIV-1 infection. J Med Virol 2000; 61:181-186.
29. Fox J, Dustan S, McClure M, Weber J, Fidler S. Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med 2006; 7:477-483.
30. CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20:21-28.
31. Pao D, Smit F, Imami N, Fisher M. A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2. AIDS 2006; 20:1564-1565.
32. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959.
33. Pillay D, Fisher M. Primary HIV infection, phylogenetics, and antiretroviral prevention. J Infect Dis 2007; 195:924-926.
34. Yeni P. Prise en charge thérapeutique des personnes infectées par le VIH. Paris: Médecine-Sciences Flammarion; 2006. [French Expert Group's recommendations for medical management of HIV infection: highlights and recommendations 2006]. French.